Emtricitabine/Maraviroc/Tenofovir Disoproxil Fumarate

恩曲他滨/马拉韦罗/富马酸替诺福韦二吡呋酯

Report date: 2025/03/19 16:22:29

Base Information

Drug NameEmtricitabine/Maraviroc/Tenofovir Disoproxil Fumarate
Drug Alias NameTenofovir Disoproxil Fumarate+Emtricitabine+Maraviroc富马酸替诺福韦二吡呋酯+恩曲他滨+马拉韦罗富马酸替诺福韦二吡呋酯/恩曲他滨/马拉韦罗Emtricitabine/tenofovir disoproxil fumarate/maravirocEmtricitabine+tenofovir disoproxil fumarate+maraviroc +[10] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsC-C chemokine receptor type 5 antagonistsReverse transcriptase inhibitors +[4] 
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseC-C chemokine receptor type 5Reverse transcriptase +[4] 
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes EmtricitabineMaravirocTenofovir Disoproxil Fumarate
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentAuritec Pharmaceuticals IncUniversity Of Texas Medical Branch +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentAuritec Pharmaceuticals IncUniversity Of Texas Medical Branch +[4] 
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A